The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Jefferies on September 17, 2024. The analyst firm set a price target for $13.00 expecting RLMD to rise to within 12 months (a possible 283.48% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Jefferies, and Relmada Therapeutics upgraded their buy rating.

The last upgrade for Relmada Therapeutics Inc happened on September 17, 2024 when Jefferies raised their price target to $13. Jefferies previously had a hold for Relmada Therapeutics Inc.

The last downgrade for Relmada Therapeutics Inc happened on June 5, 2024 when Goldman Sachs changed their price target from $3 to $2 for Relmada Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a upgraded with a price target of $3.50 to $13.00. The current price Relmada Therapeutics (RLMD) is trading at is $3.39, which is out of the analyst’s predicted range.